scispace - formally typeset
Journal ArticleDOI

4. Modelling Survival Data in Medical Research

About
This article is published in Journal of The Royal Statistical Society Series A-statistics in Society.The article was published on 1995-01-01. It has received 1092 citations till now. The article focuses on the topics: Medical research.

read more

Citations
More filters
Journal ArticleDOI

Time to default in credit scoring using survival analysis: a benchmark study

TL;DR: It is found that spline-based methods and the single event mixture cure model perform well in the credit risk context.
Journal ArticleDOI

In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma

TL;DR: PET after one cycle of chemotherapy is highly prognostic in HL, and in the absence of precise pretherapeutic predictive markers, PET1 is the best method for response-adapted strategies designed to select patients for less intensive treatment.
Journal ArticleDOI

Prognostic factors for duration of sick leave due to low-back pain in dutch health care professionals.

TL;DR: Poor prognosis for duration of Sick leave can be identified by means of a simple questionnaire administered on the first day of sick leave.
Journal ArticleDOI

A Time to Event Tutorial for Pharmacometricians

TL;DR: Hazards and how doses can be linked to events predicted from hazard functions are explained and described in this tutorial.
References
More filters
Journal ArticleDOI

Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis

TL;DR: Hyperphosphatemia and hyperparathyroidism were significantly associated with all-cause, cardiovascular, and fracture-related hospitalization, and the population attributable risk percentage for disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of hyperph phosphatemia.
Journal ArticleDOI

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

TL;DR: Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC, highlighting an improved prognosis in patients with RCC in the era of targeted therapy.
Journal ArticleDOI

Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma

TL;DR: Five prognostic factors for predicting survival were identified and used to categorize patients with metastatic RCC into three risk groups, for which the median survival times were separated by 6 months or more.